Atlas Capital Advisors’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $117K | Sell |
4,856
-247
| -5% | -$6.46K | 0.01% | 572 |
|
|
2026
Q1 | $143K | Buy |
5,103
+3,455
| +210% | +$92K | 0.02% | 472 |
|
|
2025
Q4 | $41K | Buy |
+1,648
| New | +$41.6K | ﹤0.01% | 647 |
|
|
2025
Q2 | $74.2K | Buy |
3,062
+400
| +15% | +$9.33K | 0.01% | 574 |
|
|
2025
Q1 | $67.5K | Buy |
2,662
+1,000
| +60% | +$26.2K | 0.01% | 597 |
|
|
2024
Q4 | $44.1K | Sell |
1,662
-1,240
| -43% | -$33.6K | 0.01% | 629 |
|
|
2024
Q3 | $84K | Buy |
2,902
+1,800
| +163% | +$52.5K | 0.01% | 517 |
|
|
2024
Q2 | $30.8K | Sell |
1,102
-600
| -35% | -$16.5K | ﹤0.01% | 646 |
|
|
2024
Q1 | $47.2K | Buy |
1,702
+600
| +54% | +$16.6K | 0.01% | 577 |
|
|
2023
Q4 | $31.7K | Sell |
1,102
-3,076
| -74% | -$93K | ﹤0.01% | 642 |
|
|
2023
Q3 | $139K | Sell |
4,178
-803
| -16% | -$28.4K | 0.02% | 397 |
|
|
2023
Q2 | $183K | Sell |
4,981
-1,384
| -22% | -$53.9K | 0.03% | 383 |
|
|
2023
Q1 | $260K | Sell |
6,365
-22,507
| -78% | -$972K | 0.04% | 307 |
|
|
2022
Q4 | $1.48M | Sell |
28,872
-1,369
| -5% | -$65.6K | 0.25% | 79 |
|
|
2022
Q3 | $1.32M | Sell |
30,241
-155
| -0.5% | -$7.53K | 0.24% | 80 |
|
|
2022
Q2 | $1.59M | Sell |
30,396
-2,360
| -7% | -$120K | 0.27% | 75 |
|
|
2022
Q1 | $1.7M | Buy |
32,756
+389
| +1% | +$20.2K | 0.26% | 85 |
|
|
2021
Q4 | $1.91M | Buy |
32,367
+4,321
| +15% | +$214K | 0.28% | 77 |
|
|
2021
Q3 | $1.21M | Buy |
28,046
+19,828
| +241% | +$878K | 0.19% | 99 |
|
|
2021
Q2 | $322K | Buy |
8,218
+25
| +0.3% | +$972 | 0.05% | 280 |
|
|
2021
Q1 | $297K | Sell |
8,193
-1,796
| -18% | -$63.8K | 0.06% | 272 |
|
|
2020
Q4 | $368K | Sell |
9,989
-4,714
| -32% | -$173K | 0.08% | 221 |
|
|
2020
Q3 | $512K | Sell |
14,703
-1,223
| -8% | -$42.9K | 0.12% | 179 |
|
|
2020
Q2 | $494K | Buy |
15,926
+14,570
| +1,074% | +$495K | 0.12% | 182 |
|
|
2020
Q1 | $42K | Buy |
1,356
+237
| +21% | +$8.08K | 0.01% | 458 |
|
|
2019
Q4 | $41.6K | Hold |
1,119
| – | – | 0.01% | 484 |
|
|
2019
Q3 | $38.2K | Sell |
1,119
-11,382
| -91% | -$414K | 0.01% | 480 |
|
|
2019
Q2 | $514K | Sell |
12,501
-19,036
| -60% | -$756K | 0.17% | 165 |
|
|
2019
Q1 | $1.27M | Sell |
31,537
-3,330
| -10% | -$133K | 0.46% | 62 |
|
|
2018
Q4 | $1.44M | Buy |
34,867
+33,762
| +3,055% | +$1.4M | 0.58% | 42 |
|
|
2018
Q3 | $47K | Hold |
1,105
| – | – | 0.02% | 425 |
|
|
2018
Q2 | $39.5K | Sell |
1,105
-11,948
| -92% | -$408K | 0.01% | 415 |
|
|
2018
Q1 | $440K | Buy |
+13,053
| New | +$449K | 0.13% | 200 |
|
Other funds holding PFE
Atlas Capital Advisors's PFE Position: Q2 2026 in Review
Atlas Capital Advisors reduced its Pfizer (PFE) stake by 4.8% in Q2 2026, selling an estimated $6.46K and leaving 4,856 shares worth $117K. The position accounts for 0.01% of the portfolio, ranked #572.
Atlas Capital Advisors first reported a position in PFE in Q1 2018 and has held it in 33 quarters since. The position peaked at $1.91M in Q4 2021. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Atlas Capital Advisors held 4,856 shares of Pfizer worth $117K as of Q2 2026.
- Atlas Capital Advisors sold 247 Pfizer shares in Q2 2026, an estimated $6.46K.
- Pfizer made up 0.01% of Atlas Capital Advisors's portfolio in Q2 2026, its #572 holding.
- Atlas Capital Advisors first reported a position in Pfizer in Q1 2018 and has held it in 33 quarters since.
- Atlas Capital Advisors's Pfizer position peaked at $1.91M in Q4 2021.
- 2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Atlas Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.